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TheQ1 Psychosocial and Clinical Outcomes of
Orbital Decompression Surgery for Thyroid
Eye Disease and Predictors of Change in
Quality of Life
Q15 Sadie Wickwar, MSc, PhD,1,2 Hayley McBain, PhD, CPsychol,1,3 Daniel G. Ezra, MD, FRCOpth,2,4
Shashivadan P. Hirani, PhD, CPsychol,1 Geoffrey E. Rose, DSc, FRCOphth,2,4
Stanton P. Newman, DPhil, CPsychol1
Purpose: Thyroid eye disease (TED) has been found to reduce quality of life for many patients because of
changes in their appearance and vision, although some seem to adjust better than others. This study was
designed to investigate whether a patient’s quality of life changes after having orbital decompression for
improvement of appearance, vision, or both, and whether any demographic, clinical, or psychosocial factors can
predict which patients might beneﬁt from this surgery.
Design: This study used a within-subjects repeated-measures design, in which patients were assessed
before and at 6 weeks and 6 months after surgery.
Participants: A total of 123 adults (aged >18 years) with TED and undergoing orbital decompression surgery
were recruited at Moorﬁelds Eye Hospital.
Methods: Participants received lateral wall, medial wall, 2.5 wall, or 3 wall decompression and were followed
up after surgery with a range of psychosocial and clinical assessments.
Main Outcome Measures: The Graves’ Ophthalmopathy Quality of Life (GO-QOL) scale was completed at
each time point, and this was used as the dependent variable in each hierarchical multiple regression model.
Results: Signiﬁcant improvements were found in all clinical characteristics after orbital decompression and in
most psychosocial variables. The GO-QOL visual function scores did not change signiﬁcantly until 6 months after
surgery. In contrast, GO-QOL appearance scores changed signiﬁcantly by 6 weeks after surgery and continued to
increase to 6 months, reaching a minimal clinically important difference for this scale. None of the changes in
clinical or psychosocial outcomes signiﬁcantly predicted change in GO-QOL visual function. However, the hi-
erarchical regression model explained 79% of the variance in change in GO-QOL appearance, with change in
subjective evaluation of appearance being the only unique predictor of change in appearance-related quality of
life.
Conclusions: This study highlights the importance of appearance-related cognitions in predicting quality of
life outcomes after surgery. Implications for clinical practice need to be considered in light of the limitations of this
study, but it is suggested that psychosocial interventions targeting appearance-related cognitive processes, in
particular personal evaluation of appearance, could enhance the quality of life outcomes for patients with TED
undergoing orbital decompression surgery. Ophthalmology 2015;-:1e9 ª 2015 by the American Academy of
Ophthalmology.
Supplemental material is available at www.aaojournal.org.
Thyroid eye disease (TED) requires a complex management
regimen that includes regular assessment of disease severity
and activity, these being the markers for treatment decisions.
Mild TED is characterized by mild lid retraction and soft
tissue involvement, proptosis up to 3 mm above normal,
transient or no diplopia, and corneal exposure responsive to
lubricants.1 Moderate to severe TED involves more
signiﬁcant lid retraction (>2 mm), soft tissue involvement,
proptosis more than 3 mm above normal limits, and
constant or inconstant diplopia, having a substantial impact
on daily activities.1 Approximately 10% of patients develop
the severest forms of TED that are sight-threatening and
require immediate intervention.2 Orbital decompression
surgery is one of a number of possible interventions for
TED but is a major surgery involving the removal of fat,
bone, or a combination of both from the orbits. Thus, it is
only offered to patients with moderate to marked proptosis
with inactive disease or active and sight-threatening TED.2,3
1 2015 by the American Academy of Ophthalmology
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Thyroid eye disease has been found to have a signiﬁcant
impact on quality of life related to both appearance and
vision before rehabilitative surgery,4e6 but less is known
about quality of life after the rehabilitative surgeries offered
to patients with TED. Evidence to date suggests there is
variability in quality of life after orbital decom-
pression,3,7e10 but the limited quality of prior studies, some
with inadequate sample size, means that there is limited
reliable evidence for the psychosocial beneﬁts of this major
surgery for TED.11
Reconstructive surgery is commonly founded on the belief
that an improvement in the appearance of a disﬁguring con-
dition will lead to improved quality of life.12 Many patients
are pleased with the outcome of aesthetic enhancing
procedures, but some report dissatisfaction.13,14 Recent
studies have suggested that reduced levels of psychologic
distress will only follow if surgery reduces subjective noti-
ceability of a condition, regardless of an objectively suc-
cessful result.15 With increasing evidence that questions the
relationship between clinical factors and quality of life,16
there is a greater focus on examining the individual
psychologic factors that might predict patients’ psychologic
adjustment to the changes in vision and appearance caused
by TED.17 Other than quality of life, there is a wealth of
psychosocial factors that have not been assessed after
surgery for TED, and these factors could explain some of
the variance between participants that is unexplained by
clinical factors. Potentially relevant factors include
appearance concerns, fear of the negative evaluation of
others, social comparisons, and subjective visibility, which
have been found to signiﬁcantly explain variability in
quality of life after realignment surgery for strabismus.18
Identifying factors that predict psychologic outcomes
after reconstructive and aesthetic surgery has become a
priority in recent years.14 In the context of TED, this would
enable practitioners to target speciﬁc psychologic processes
when developing interventions to improve quality of life.
Few studies have examined how potential psychosocial
factors could explain quality of life after surgery in
patients with TED.11 Given that decompression is major
surgery and patients can have unrealistic expectations that
it will return them to their “normal” premorbid state,19 an
investigation of this nature is long overdue.
This study was designed to establish whether orbital
decompression in patients with TED has an impact on
quality of life and other psychosocial factors, the extent to
which quality of life outcomes can be predicted using
clinical and psychosocial measures at the time of presenta-
tion, and whether postoperative changes in the clinical and
psychosocial factors could explain changes in quality of life.
Methods
Ethics
Ethical approval was obtained from the North London Research
Ethics Committee (reference 11/H0724/6). Decompression of up to
3 orbital walls is part of the usual treatment at Moorﬁelds Eye
Hospital, and the study adhered to the tenets of the Declaration of
Helsinki. Informed consent was obtained from all participants.
Study Design
This study used a within-subjects repeated-measures design,
whereby patients were assessed before surgery and again 6 weeks
and 6 months postsurgery.
Participants
Participants were recruited from Moorﬁelds Eye Hospital, London.
Patients aged 18 years or older who had received a consultant-led
diagnosis of TED were approached by a researcher (SW) on the
day they were listed for orbital decompression surgery and invited
to take part in the study. Patients were excluded from the study if
they did not have a comprehensive understanding of English (as
identiﬁed by the consultant) or their consultant considered them too
ill or distressed to take part in the study.
Measures
Participants were asked to provide demographic details before
orbital decompression. They also completed a range of psychoso-
cial questionnaires before and 6 weeks and 6 months after surgery.
Treating clinicians provided clinical measurements at these same
time points, which reﬂect standard follow-up times after orbital
decompression surgery at Moorﬁelds Eye Hospital.
Demographic and Clinical Measures
Self-reported age, gender, and ethnic background were collected
before surgery. Participants were given a list of 11 categories that
classify the various ethnic groups or backgrounds (Ofﬁce for Na-
tional Statistics, 2003) and asked to tick the box that best described
their background. Clinical measures were collected by a clinician at
each of the 3 study time points and included the length of time
TED had been present (disease duration), stability of thyroid
function, treatment history, laterality of TED and planned surgery,
smoking status, upper and lower margin reﬂex distances 1 and 2
(millimeters), and the presence of superﬁcial punctate keratitis
(SPK), diplopia, or congestive orbital disease. Congestive orbital
disease is associated with increased intraocular pressure, deep
orbital vascular congestion, and optic neuropathy and is sometimes
termed “hydraulic orbit.”20 Disease activity was measured using
the widely used Clinical Activity Scale (CAS),21 a 10-item mea-
sure of pain, redness, swelling, and impaired orbital function.
Snellen visual acuity was measured for each eye22 and converted to
logarithm of the minimum angle of resolution; logarithm of the
minimum angle of resolution values range between 0.20 and
2.1. A score of 2.2 was assigned to patients with counting-
ﬁngers vision or worse. Optic neuropathy was considered present
with abnormal Ishihara color testing (if not color-blind), and testing
for a relative afferent pupillary defect was used in addition.
Proptosis (millimeters) was assessed with an exophthalmometer
(Oculus Q4), and the degree of asymmetry between eyes was noted.
The need for further surgery after orbital decompression was
recorded at each follow-up.
Primary Outcome Measure
The Graves’ Ophthalmopathy Quality of Life (GO-QOL) ques-
tionnaire is a validated disease-speciﬁc measure8 that has been
recommended for investigation of treatments for TED.23 The
GO-QOL consists of 2 subscales: vision-related quality of life
and appearance-related quality of life.8 The Australian version of
the GO-QOL4 has been used in this study, because an item
about “bicycling” has been replaced by 2 more culturally
relevant items about “limitations in work” and “domestic duties.”
Subscale scores were calculated following questionnaire
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guidelines,8 and higher scores on each subscale indicate better
health-related quality of life.
Psychosocial Measures
Participants were asked to complete a range of questionnaires at
each time point. These were selected from a framework of
adjustment to TED developed by the research teamQ5 (Fig 1), adapted
from The Appearance Research Collaboration’s24 framework of
adjustment to living with a disﬁgurement. The original version of
the framework contains the constructs that have been
demonstrated to be involved in psychologic adjustment to
appearance-altering conditions in a body of research on the psy-
chology of appearance. Appearing ﬁrst in the framework are the
predisposing factors, or social context, in which adjustment takes
place, including demographic characteristics and clinical factors,
such as disease severity. Next are the intervening cognitions, or
thought processes, that have been identiﬁed as potentially useful in
explaining the difference in adjustment from patient to patient.
These have been grouped into the following: social cognitions,
which include fearing others’ negative evaluations, making com-
parisons with others in a social context and perceptions of social
support; appearance-speciﬁc cognitions, including appearance-
related distress, perceptions of own appearance (valence of
appearance), the importance of appearance (salience of appear-
ance), and perceived visibility of the disﬁgurement; and mood,
which includes anxiety and depression. Psychologic well-being, or
quality of life, features in the framework as the outcome of
adjustment to living with a disﬁguring condition. The choice of
questionnaires for this study was based on the concepts from the
framework identiﬁed as important predictors of quality of life in
TED in a previous study.17
Existing validated measures and brief versions of question-
naires were used where possible and are described as follows:
The Brief Fear of Negative Evaluation scale25 measures the
extent to which an individual is concerned by others’ opinions of
them. This validated tool consists of 12 items, and higher scores
indicate a greater fear of negative evaluation from others.
The Iowa-Netherlands Comparison Orientation Measure26
measures how well respondents feel they are doing in life when
comparing himself or herself to others. Higher scores on this
validated 11-item tool indicate a greater tendency to make social
comparisons.
The Multidimensional Scale of Perceived Social Support27
measures subjective levels of social support from family, friends,
and signiﬁcant others. Higher scores on each 4-item subscale
indicate greater perceived social support.
The Derriford Appearance Scale 2428 measures the impact of
appearance-related distress on social anxiety and avoidance.
Higher scores on this validated brief questionnaire represent greater
levels of appearance-related distress and social avoidance.
The Centre for Appearance Research Valence Scale and Centre
for Appearance Research Salience Scale29 measure how an
individual evaluates his or her own physical appearance (Centre
for Appearance Research Valence Scale) and the extent to which
physical appearance is important to the individual (Centre for
Appearance Research Salience Scale). Higher scores on each
brief measure indicate a more negative self-evaluation of appear-
ance and that greater value is placed on appearance, respectively.
Perceived Visibility of Graves’ ophthalmology (GO Q6): Patients
were asked to rate how visible they thought their proptosis was to
other people on a 7-point Likert scale from 1 (not at all visible) to 7
(extremely visible).
The Hospital Anxiety and Depression Scale30 is designed to
screen for depression and anxiety in patients with health
problems. Higher total subscale scores on this validated measure
indicate greater levels of anxious or depressed mood. Cutoff
scores were also applied to identify noncases (0e7), doubtful
cases (8e10), and cases of possible clinical anxiety or depression
(scores of 11).
Statistical Analyses
An estimate of sample size was based on the required size for
multilevel modeling, which assumes a hierarchical structure,
whereby data are organized to reﬂect that time is nested within the
Figure 1. The potential variables to be used in the hierarchical multiple regression to explore factors associated with quality of life. Framework adapted from
Clarke et al.24 BFNE ¼ Brief Fear of Negative Evaluation; CARSAL ¼ Centre for Appearance Research Salience Scale; CARVAL ¼ Centre for
Appearance Research Valence Scale; CAS ¼ Clinical Activity Scale; DAS24 ¼ Derriford Appearance Scale 24; GO-QOL ¼ Graves’ Ophthalmopathy
Quality of Life; HADS ¼ Hospital Anxiety and Depression Scale; INCOM ¼ Iowa-Netherlands Comparison Orientation Measure; logMAR ¼ logarithm of
the minimum angle of resolution; MRD1 ¼ margin reﬂex distance 1; MRD2 ¼ margin reﬂex distance 2; MSPSS ¼ Multidimensional Scale of Perceived
Social Support; SPK ¼ superﬁcial punctate keratitis; TED ¼ thyroid eye disease.
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participant. Recent recommendations suggest that 20 to 60 par-
ticipants should be recruited for each level in the structure.31,32
Because this study used 2 levels (time and participant), a mini-
mum sample of 40 and a maximum of 120 were required. Multi-
level modeling examined the signiﬁcance of changes over time,
from before to after surgery. To examine whether signiﬁcant
change was seen between each time point, pairwise comparisons
were performed on adjusted mean scores. Effect sizes were
calculated using partial eta-squared (s2p) when data were contin-
uous, and the odds ratios (Expb) were calculated when data were
categoric. The clinical variables optic neuropathy, SPK, diplopia,
and congested orbit were the only variables assessed categorically.
Hierarchical multiple regressions were used to assess (1)
whether any factors measured at baseline could predict the direc-
tion of change in quality of life (from before to after surgery) and
(2) whether any factors measured before and after surgery that were
found to alter with the surgery could predict the change in quality
of life. Residualized change scores were calculated by regressing
the variable at time 1 (baseline score) from the same variable at
time 3 (6-month postoperative score). Variables entered into each
regression model were chosen on the basis of their signiﬁcance in
predicting each dependent variable (the GO-QOL subscales) in
prior univariate regression analyses (P < 0.05); the order used to
enter the predictors into the regression was based on the framework
outlined in Figure 1. Entry methods were used for the hierarchical
regressions, and Cohen’s f2 was used to calculate effect sizes of
each of these regressions.
As a means of a sensitivity analysis, patients who had
completed only the baseline questionnaire were compared with
those who completed both this and at least 1 follow-up question-
naire, using t tests and Pearson’s chi-square tests (signiﬁcance set
to 0.05).
Results
Participants
A total of 192 patients were identiﬁed as eligible for the research.
Of these, 135 (70%) agreed to take part, and 123 of the 135 (91%)
returned their initial questionnaire. Two participants were removed
from the baseline analysis because of high proportions of missing
data (>50%). Because of small numbers of patients in some cat-
egories of ethnic background, this was collapsed into 3 groups:
white ethnic background, Asian ethnic background, and black
ethnic background. Of the 121 participants assessed before surgery
and described in a previous publication,17 84 (69%) responded to
the 6-week follow-up questionnaire after their surgery and 86
(71%) responded to the 6-month follow-up questionnaire. Analysis
of differences between responders and nonresponders found that
patients of white ethnic background were more likely to respond to
follow-up than other ethnic groups (chi-square [1]¼4.79, P <
0.05), as were nonsmokers (chi-square [3]¼11.43, P < 0.05).
Baseline characteristics of the study sample are shown in Table 1.
Postoperative Changes
All clinical variables changed signiﬁcantly after surgery, as shown
in Tables 2 (continuous variables) and 3 (categoric variables): For
continuous variables (proptosis, asymmetry, visual acuity, lid
retraction, and activity), most improvement occurred by 6 weeks
after surgery, with no further statistically signiﬁcant changes
between 6 weeks and 6 months. This effect was also observed
for the categoric variables optic neuropathy and congestive
orbital disease. However, for the presence of SPK and diplopia,
statistically signiﬁcant improvements were not observed until 6
months after surgery.
Statistically signiﬁcant improvements were also observed in the
majority of psychosocial variables, with the exception of social
support and social comparison (Table 4). Improvements in
appearance-related quality of life, mood, appearance-related so-
cial anxiety and avoidance, valence and salience of appearance,
and perceived visibility were found 6 weeks after surgery and were
maintained 6 months later. Changes in appearance-related quality
of life reached a large minimal clinically important difference, but
vision-related quality of life failed to improve statistically until 6
months after surgery, as did fear of negative evaluation (Table 4).
Appearance-related quality of life remained lower than vision-
related quality of life (Fig 2), and a large variation between
participants was observed (Table 4).
Table 1. Baseline Characteristics for the Study Group of 121
Patients with Thyroid Eye Disease Being Considered for Orbital
Decompression
Variable No. (%) Range Mean ± SD
Age (yrs) 22e79 47.112.3
Gender
Male 33 (27%)
Female 88 (73%)
Ethnicity
Asian 11 (9.1%)
White British/Irish/other 95 (79%)
Black African/Caribbean/
other
15 (12%)
Relationship status
Married/living with partner 73 (60%)
Single/other 48 (40%)
Disease duration (mos) 4e336 62.042
Laterality of TED
Bilateral 101 (83%)
Unilateral 20 (17%)
Laterality of planned surgery
Bilateral 79 (65%)
Unilateral 42 (35%)
Treatment history
Previous immunosuppression 58 (48%)
Previous radiotherapy 18 (15%)
Previous surgery 14 (12%)
Thyroid function
Stable 106 (88%)
Unstable 15 (12%)
Visual acuity (logMAR
conversion)*
0e2 0.10.4
Corneal SPK 39 (32%)
Congested orbit 25 (21%)
Optic neuropathy 15 (12%)
Diplopia 62 (51%)
Margin reﬂex distance 1 (mm)* 1.5e13 5.922.1
Margin reﬂex distance 2 (mm)* 4e11 6.731.4
Exophthalmometry (mm)* 15e33 23.72.7
Asymmetry (mm) 0e8 1.81.8
CAS 0e9 1.121.9
Smokers 38 (31%)
CAS ¼ Clinical Activity Scale; logMAR ¼ logarithm of the minimum
angle of resolution; SD ¼ standard deviation; SPK ¼ superﬁcial punctate
keratitis; TED ¼ thyroid eye disease.
*--- Q9
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Because the majority of change was found at the 6-month
follow-up, residualized change scores were calculated for the
change from baseline to 6-month scores after surgery for each of
the dependent variables described in the following sections.
Predictors of Change in Quality of Life Measured at
Baseline
Vision-Related Quality of Life. Univariate linear regressions
indicated that the only statistically signiﬁcant preoperative pre-
dictors of change in GO-QOL visual function included ethnic
background (F(1,83)¼5.11, P < 0.05, f
2¼0.06), congested orbits
(F(1,81)¼6.24, P < 0.05, f
2¼0.08), diplopia (F(1,82)¼4.74, P <
0.05, f2¼0.06), and CAS (F(1,83)¼11.13, P < 0.05, f
2¼0.10).
Because these variables feature in the “predisposing factors”
category in Figure 1, the variables were entered in 2 steps (ethnic
background, then clinical factors). This model of ethnic
background and clinical factors explained only 16% of the
observed variance in the change in GO-QOL visual function
(R2 ¼ 0.16, F(4,78)¼3.74, P < 0.05, f
2¼0.19). Beta coefﬁcients
indicated that although the overall model was signiﬁcant, there was
no single signiﬁcant predictor measured at baseline of change in
vision-related quality of life after surgery (Table 5, available at
wwwaaojournal.org).
Appearance-Related Quality of Life. The only statistically
signiﬁcant predictors of change in GO-QOL appearance measured
before surgery included ethnic background (F(1,83)¼4.75, P <
0.05, f2¼0.06), previous radiotherapy (F(1,74)¼4.19, P < 0.05,
f2¼0.06), congested orbit (F(1,81)¼4.72, P < 0.05, f
2¼0.06),
diplopia (F(1,82)¼8.46, P < 0.05, f
2¼0.10), and CAS (F(1,83)¼7.88,
P < 0.05, f2¼0.09). As previously, variables were entered into the
regression in 2 steps. This regression model accounted for 20% of
the observed sample variation in the change in GO-QOL appear-
ance (R2 ¼ 0.20, F(4,70)¼3.17, P < 0.05, f
2¼0.25). Beta
Table 2. Adjusted Means for Continuous Clinical Variables before (Baseline) and after (6 Weeks and 6 Months) Surgery and Analysis of
Variance (F) with Respect to Time
Variable
Baseline
(M ± SD)
6 Weeks
(M ± SD)
6 Months
(M ± SD)
Variance Analysis with
Respect to Time
Effect Size
(s2p)
Baseline to
6 Weeks
Baseline to
6 Months
Exophthalmometry 23.72.45 19.32.41 19.12.39 F 2, 149.80¼252, P < 0.001
y 0.77 4.41, P < 0.001y 4.58, P < 0.001y
Asymmetry 1.841.48 0.831.48 0.751.47 F 2, 161.90¼20.2, P < 0.001
y 0.20 1.02, P < 0.001y 1.09, P < 0.001y
logMAR 0.080.25 0.000.25 0.010.24 F 2, 160.40¼4.53, P < 0.05* 0.05 0.08, P ¼ 0.029* 0.09, P ¼ 0.031*
MRD1 6.001.82 5.291.78 5.291.79 F 2,145.94¼8.26, P < 0.001
y 0.10 0.71, P ¼ 0.001* 0.71, P ¼ 0.004*
MRD2 6.771.25 5.461.25 5.471.25 F 2,156.65¼46.4, P < 0.001
y 0.37 1.31, P < 0.001y 1.30, P < 0.001y
CAS 1.171.44 0.641.42 0.401.43 F 2,155.20¼9.41, P < 0.001
y 0.11 0.53, P ¼ 0.007* 0.77, P < 0.001y
Estimated marginal means.
CAS ¼ Clinical Activity Scale; logMAR ¼ logarithm of the minimum angle of resolution; MRD1 ¼ margin reﬂex distance 1; MRD2 ¼ margin reﬂex
distance 2; SD ¼ standard deviation.
*P < .05.
yP < .001.
Table 3. Frequencies of Categoric Clinical Variables before (Baseline) and after (6 Weeks and 6 Months) Surgery, and Probabilities of
Presence with Respect to Time
Model Parameter
Baseline
No. (%)
6 Weeks
No. (%)
6 Months
No. (%) b
Standard
Error b
Wald
Chi-Square P Exp(b)
95% CI
for Exp(b)
Optic neuropathy 12 (11.2) 4 (3.7) 2 (1.9)
Intercept 2.07 0.31 45.67 <0.001Q10 y 0.13 0.069e0.230
6 wks vs baseline 1.13 0.50 5.08 0.024* 0.32 0.121e0.863
6 mos vs baseline 1.55 0.61 6.33 0.012* 0.21 0.064e0.711
Punctate keratopathy 33 (72) 27 (25.2) 13 (12.1)
Intercept 0.77 0.21 13.77 <0.001y 0.46 0.307e0.695
6 wks vs baseline 0.22 0.27 0.66 0.418 0.80 0.469e1.369
6 mos vs baseline -1.02 0.34 8.91 0.003* 0.36 0.185e0.705
Diplopia 56 (52.3) 51 (47.7) 38 (35.5)
Intercept 0.08 0.19 0.15 0.696 1.08 0.74e1.571
6 wks vs baseline 0.03 0.22 0.02 0.891 0.97 0.637e1.481
6 mos vs baseline 0.50 0.23 4.58 0.032* 0.61 0.383e0.959
Congested orbit 20 (18.7) 3 (2.8) 5 (4.7)
Intercept 1.43 0.25 33.27 <0.001y 0.24 0.146e0.388
6 wks vs baseline 2.03 0.65 9.61 0.002* 0.13 0.037e0.474
6 mos vs baseline 1.43 0.52 7.57 0.006* 0.24 0.086e0.662
CI ¼ conﬁdence interval.
*P < 0.05.
yP < 0.001.
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coefﬁcients indicated that although the overall model was signiﬁ-
cant, there was no single predictor measured at baseline of change
in appearance-related quality of life at 6 months after surgery
(Table 6, available at www.aaojournal.org).
Predictors of Change in Quality of Life Measured
before and after Surgery
Vision-Related Quality of Life. Residualized change scores
were calculated for all predictive variables. Eight change variables
independently predicted change in visual GO-QOL to a signiﬁcant
level: change in diplopia (F(1,72)¼5.88, P < 0.05, f
2¼0.08), change
in support from signiﬁcant others (F(1,81)¼5.51, P < 0.05,
f2¼0.07), change in fear of negative evaluation (F(1,71)¼5.30, P <
0.05, f2¼0.07), change in social comparison (F(1,77)¼4.36, P <
0.05, f2¼0.06), change in social anxiety and social avoidance
(F(1,28)¼6.26, P < 0.05, f
2¼0.22), change in valence of appearance
(F(1,39)¼6.86, P < 0.05, f
2¼0.18), change in anxious mood
(F(1,82)¼10.56, P < 0.05, f
2¼0.13), and change in depressed mood
(F(1,79)¼20.51, P < 0.001, f
2¼0.26). The regression model was not
signiﬁcant (R2 ¼ 0.36, F(8,16)¼1.12, P ¼ 0.40, f
2¼1.29) (Table 7,
available at www.aaojournal.org), thus suggesting that none of the
variables measured before and after surgery could predict the
change observed in vision-related quality of life.
Table 4. Adjusted Means for Continuous Psychosocial Variables before (Baseline) and after (6 Weeks and 6 Months) Surgery, and
Variance Analysis (F) with Respect to Time
Measures
Baseline
(M ± SD)
6 Weeks
(M ± SD)
6 Months
(M ± SD)
Variance Analysis with
Respect to Time
Effect
Size (s2p)
Baseline to
6 Weeks
Baseline to
6 Months
GO-QOL visual
function
63.4vv29.3Q11 65.027.4 71.427.8 F 2, 130.52[5.302 , P [ 0.006* 0.08 1.60, P ¼ 0.873 8.02, P [ 0.008*
GO-QOL
appearance
35.426.2 48.724.7 54.925.1 F 2, 131.55[31.0, P < 0.001
y 0.32 13.23, P < 0.001y 19.46, P < 0.001y
HADS anxiety 9.434.52 7.234.20 7.044.29 F 2, 156.80[27.0, P < 0.001
y 0.26 2.21, P < 0.001y 2.40, P < 0.001y
HADS
depression
7.874.52 6.094.21 5.814.32 F 2, 120.04[14.9, P < 0.001
y 0.20 1.77, P < 0.001y 2.06, P < 0.001y
DAS24 52.214.2 44.114.3 41.215.4 F 2, 68.01[17.2, P < 0.001
y 0.34 8.11, P < 0.001y 11.04, P < 0.001y
CARSAL 25.45.41 23.44.92 23.25.28 F 2, 102.71[5.96, P [ 0.004* 0.10 1.95, P [ 0.006* 2.17, P [ 0.013*
CARVAL 41.39.66 34.09.65 31.89.88 F 2, 90.99[21.9, P < 0.001
y 0.33 7.24, P < 0.001y 9.50, P < 0.001y
Visibility 5.761.68 4.011.62 3.751.63 F 2, 157.24[58.6, P < 0.001
y 0.43 1.76, P < 0.001y 2.01, P < 0.001y
MSPSS friends 15.33.86 15.33.56 15.53.66 F 2, 110.52¼0.23, P ¼ 0.794 0.01 0.01, P ¼ 1.000 0.20, P ¼ 0.935
MSPSS family 15.54.12 16.13.84 15.63.91 F 2, 131.88¼1.95, P ¼ 0.147 0.03 0.64, P ¼ 0.195 0.10, P ¼ 0.991
MSPSS signiﬁcant
other
15.94.69 16.04.26 16.24.43 F 2, 161.38¼0.27, P ¼ 0.766 0.01 0.29, P ¼ 0.987 0.29, P ¼ 0.858
BFNE 38.18.95 36.78.28 36.18.39 F 2, 102.80[3.93, P [ 0.023* 0.07 1.46, P ¼ 0.054 2.02, P [ 0.033*
INCOM 35.96.80 35.16.46 35.66.54 F 2, 133.57¼0.73, P ¼ 0.485 0.01 0.77, P ¼ 0.545 0.35, P ¼ 0.936
Estimated marginal means. Q14
BFNE ¼ Brief Fear of Negative Evaluation; CARSAL ¼ Centre for Appearance Research Salience Scale; CARVAL ¼ Centre for Appearance Research
Valence Scale; DAS24 ¼ DAS24 ¼ Derriford Appearance Scale 24; GO-QOL ¼ Graves’ Ophthalmopathy Quality of Life; HADS ¼ Hospital Anxiety and
Depression Scale; INCOM ¼ Iowa-Netherlands Comparison Orientation Measure; MSPSS ¼ Multidimensional Scale of Perceived Social Support; SD ¼
standard deviation.
*P < 0.05.
yP < 0.001.
Figure 2. Time-related change in Graves’ Ophthalmopathy Quality of Life (GO-QOL) subscale scores with standard deviation error bars.
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Appearance-Related Quality of Life. Ten variables inde-
pendently predicted change in GO-QOL appearance to a signiﬁcant
degree: change in upper eyelid retraction (F(1,69)¼4.54, P < 0.05,
f2¼0.07), change in congested orbit (F(1,73)¼4.94, P < 0.05,
f2¼0.07), change in support from signiﬁcant others (F(1,81)¼7.22,
P < 0.05, f2¼0.09), change in family support (F(1,82)¼5.72, P <
0.05, f2¼0.07), change in fear of negative evaluation (F(1,71)¼9.88,
P < 0.05, f2¼0.14), change in valence of appearance
(F(1,39)¼51.86, P < 0.001, f
2¼1.3), change in social anxiety and
social avoidance (F(1,28)¼19.67, P < 0.001, f
2¼0.70), change in
perceived visibility (F(1,75)¼17.08, P < 0.001, f
2¼0.23), change in
anxious mood (F(1,82)¼11.71, P ¼ 0.001, f
2¼0.14), and change in
depressed mood (F(1,79)¼29.57, P < 0.001, f
2¼0.37). When these
variables were entered into the model, they accounted for 79% of
the variation in GO-QOL appearance change from baseline to 6
months (R2 ¼ 0.79, F(11,13)¼4.55, P < 0.05, f
2¼3.76). Improve-
ment in subjective evaluation of appearance was the only variable
to provide a unique contribution to predicting improvement in
appearance-related quality of life from before to 6 months after
surgery (Table 8, available at www.aaojournal.org).
Discussion
This study was designed to establish what impact orbital
decompression surgery might have on clinical and psycho-
social well-being, whether before surgery we can predict
how well patients adjust, and whether changes in clinical
and psychosocial factors from before surgery to 6 months
afterward can explain changes in quality of life.
Despite the resolution of optic neuropathy as early as 6
weeks after surgery, vision-related quality of life did not
signiﬁcantly change until 6 months after surgery and did not
reach a minimal clinically important difference. It is possible
that presence of double vision until 6 months after surgery
might explain a continued lack of ability to carry out daily
activities, including reading and driving. Double vision at
baseline did contribute to the model that aimed to explain
change in vision-related quality of life after surgery.
Conversely, appearance-related quality of life improved
signiﬁcantly at 6 weeks and continued to signiﬁcantly
improve up to 6 months after surgery, reaching a large
minimal clinically important difference. In this sample, it
seems that orbital decompression has the biggest impact on
appearance-related quality of life and is less effective at
improving vision-related outcomes. Signiﬁcant improve-
ments in appearance-related quality of life have been
observed after orbital decompression surgery in previous
studies,8,10 although vision-related quality of life was found
to show more improvement in previous studies.3,9,10 How-
ever, our sample was somewhat different before surgery
because less patients were affected by their vision. This is
supported by the small percentage of the sample experi-
encing optic neuropathy before surgery.
Orbital decompression surgery attempts to improve
clinical factors in TED that cause pain, discomfort, and an
altered appearance. Proptosis, eyelid retraction, optic neu-
ropathy, visual acuity, and congestive orbital disease were
all found to improve as early as 6 weeks after surgery in this
study, supporting the effectiveness of orbital decompression
at improving these clinical outcomes. Some other variables
seem to take longer to demonstrate improvement, including
superﬁcial keratitis and double vision.
Appearance-related social anxiety and avoidance,
importance of appearance, personal evaluation of appear-
ance, perceived visibility of TED, and mood were all found
to improve as early as 6 weeks after surgery. Fear of
negative evaluation was found not to improve until 6
months after surgery, suggesting that the emotions associ-
ated with social factors take some time to change after
surgery. This ﬁnding supports previous research that has
found patients often need considerable time to adjust to
changes in facial appearance and might still be unsure about
the reactions of others after orthognathic surgery.33
Perceptions of social support from friends, family, and
signiﬁcant others remained the same over time. The
tendency to make social comparisons was also found not
to change after surgery, suggesting that this is a more
stable characteristic.
Ethnic background was the sole demographic variable
predicting change in quality of life with surgery: Patients
who identiﬁed themselves as being from a nonwhite ethnic
group experienced greater improvements in both vision- and
appearance-related quality of life, compared with patients
who identiﬁed themselves as from a white ethnic group.
Individuals from nonwhite ethnic backgrounds have been
found to report more worry about their appearance and an
increase in perceived noticeability when they have a visible
difference,16 suggesting that this greater improvement after
surgery might be due to a worse perception of their
appearance before treatment. Ethnic background and a
number of preoperative clinical variables were found to
predict a small proportion of the variation in quality of
life changes with surgery. None of these variables
provided a unique contribution to the model, however,
and a large proportion of the variance remains
unexplained. Therefore, surgeons should be cautious about
assuming that patients with particular disease severity or
attitude toward their own appearance will adjust poorly
after surgery. It is possible that factors not measured in
this study might better explain change in some areas of
quality of life, and links have been made in recent years
between unmet expectations and poor psychosocial
adjustment after surgery.14
Improvements in eyelid retraction and congested orbit
did not predict change in appearance-related quality of life
when entered into the model with intervening cognitive
process variables. These ﬁndings reﬂect previous surgical
studies in TED that have found weak correlations between
clinical changes and quality of life outcomes.8,34 The notion
that subjective appraisals of appearance will predict psy-
chologic well-being better than clinical measures of
severity15 also has been supported. In patients with
strabismus, personal evaluation of appearance has been
found to be a more important factor in predicting
adjustment than other clinical factors.18 This ﬁnding has
highlighted an important intervening psychosocial factor
to consider when developing future psychosocial
interventions to help improve outcomes of surgery for
patients with TED.
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Study LimitationsQ7
There are limitations to the present study. Orbital decom-
pression is part of a treatment pathway, with some patients
undergoing further surgery (e.g., eyelid lowering), and the
6-month follow-up did not assess the longer-term beneﬁts of
decompression or whether quality of life continued to
improve after such further surgery. Establishing the long-
term beneﬁts of decompression and additional surgery
would aid clinicians when informing patients about how
much they might beneﬁt from these various surgeries to
improve their appearance and, ultimately, their quality of
life. It would also be beneﬁcial to establish whether not
meeting patients’ expectations of orbital decompression
could inﬂuence their quality of life outcomes after surgery,
as suggested in the context of aesthetic surgery.13,14
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Table 5. Results of Hierarchical Regression With Change in GO-
QOL Visual Function as the Dependent Variable and Baseline
Demographic and Clinical Factors as the Predictive Variables
b Coefﬁcient
Standard
Error b t P
Constant 0.69 0.25 2.75 0.007Q13 *
Ethnicity 0.48 0.27 1.82 0.073
CAS 0.11 0.07 1.68 0.097
Hydraulic orbit 0.18 0.33 0.54 0.592
Diplopia 0.26 0.22 1.19 0.237
Note. R2 ¼ 0.06 for Step 1 (P < 0.05), R2 ¼ 0.16 for Step 2 (P < 0.05).
CAS ¼ Clinical Activity Scale; GO-QOL ¼ Graves’ Ophthalmopathy
Quality of Life.
Table 6. Results of Hierarchical Regression With Change in GO-
QOL Appearance as the Dependent Variable and Baseline De-
mographic and Clinical Factors as the Predictive Variables
b Coefﬁcient
Standard
Error b t P
Constant 0.80 0.26 2.94 0.004*
Ethnicity 0.50 0.28 1.80 0.077
Prior radiotherapy 0.60 0.40 1.41 0.164
Hydraulic orbit 0.01 0.34 0.02 0.987
Diplopia 0.37 0.23 1.59 0.118
CAS 0.10 0.07 1.54 0.127
Note. R2 ¼ 0.05 for Step 1 (P < 0.05), R2 ¼ 0.20 for Step 2 (P < 0.05).
CAS ¼ Clinical Activity Scale; GO-QOL [ Graves’ Ophthalmopathy
Quality of Life.
Table 7. The Final Step of the Hierarchical Multiple Regression
Model to Examine Change Predictors of Change in GO-QOL
Visual Function at 6 Months After Surgery
b Coefﬁcient
Standard
Error b t P
Constant 1.69 0.20 0 1.0
Diplopia 0.29 0.25 1.16 0.264
MSPSS Signiﬁcant other 0.09 0.21 0.44 0.669
BFNE 0.01 0.26 0.03 0.981
INCOM 0.23 0.26 0.87 0.399
CARVAL 0.03 0.30 0.10 0.921
DAS24 0.30 0.30 1.01 0.327
HADS Anxiety 0.06 0.27 0.22 0.832
HADS Depression 0.16 0.28 0.56 0.582
Note. R2 ¼ 0.08 for Step 1 (P ¼ 0.184), R2 ¼ 0.21 for Step 2 (P ¼ 0.343),
R2 ¼ 0.34 for Step 3 (P ¼ 0.218), R2 ¼ 0.36 for Step 4 (P ¼ 0.754).
BFNE ¼ Brief Fear of Negative Evaluation; CARVAL ¼ Centre for
Appearance Research Valence Scale; DAS24 ¼ Derriford Appearance
Scale 24; GO-QOL ¼ Graves’ Ophthalmopathy Quality of Life; HADS ¼
Hospital Anxiety and Depression Scale; INCOM ¼ Iowa-Netherlands
Comparison Orientation Measure; MSPSS ¼ Multidimensional Scale of
Perceived Social Support.
Table 8. Final Step of the Hierarchical Regression Model Used to
Examine Predictors of Change in GO-QOL Appearance 6 Months
After Surgery
b Coefﬁcient
Standard
Error b T P
Constant 1.80 0.12 0.00 1.000
MRD1 0.25 0.16 1.59 0.136
Hydraulic orbit 0.04 0.15 0.26 0.796
INCOM 0.11 0.16 0.70 0.497
BFNE 0.16 0.17 0.97 0.349
MSPSS Signiﬁcant other 0.10 0.16 0.64 0.530
MSPSS Family 0.10 0.18 0.55 0.593
CARVAL L0.64 0.19 L3.42 0.005*
DAS24 0.24 0.21 1.19 0.255
Perceived visibility 0.03 0.17 0.19 0.850
HADS Anxiety 0.25 0.17 1.44 0.173
HADS Depression 0.22 0.18 1.24 0.235
Note. R2 ¼ 0.12 for Step 1 (P ¼ 0.246), R2 ¼ 0.39 for Step 2 (P ¼ 0.141),
R2 ¼ 0.75 for Step 3 (P ¼ 0.003), R2 ¼ 0.79 for Step 4 (P ¼ 0.300).
BFNE ¼ Brief Fear of Negative Evaluation; CARVAL ¼ Centre for
Appearance Research Valence Scale; DAS24 ¼ Derriford Appearance
Scale 24; GO-QOL[ Graves’ Ophthalmopathy Quality of Life; HADS ¼
Hospital Anxiety and Depression Scale; INCOM ¼ Iowa-Netherlands
Comparison Orientation Measure; MRD1 ¼ margin reﬂex distance 1;
MSPSS ¼ Multidimensional Scale of Perceived Social Support.
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The Psychosocial and Clinical Outcomes of Orbital Decompression
Surgery for Thyroid Eye Disease and Predictors of Change in Quality of
Life
000
Sadie Wickwar, MSc, PhD, Hayley McBain, PhD, CPsychol, Daniel G. Ezra, MD, FRCOpth,
Shashivadan P. Hirani, PhD, CPsychol, Geoffrey E. Rose, DSc, FRCOphth, Stanton P. Newman,
DPhil, CPsychol
By using the Graves’ Ophthalmopathy Quality of Life scale, appearance-related quality of life
improved signiﬁcantly as a result of orbital decompression surgery for people with thyroid eye
disease, and this is better explained by improvements in psychologic factors than clinical
factors.
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